XRTX XORTX Therapeutics: מכפיל שווי פעילות להכנסות

XORTX Therapeutics Inc. is developing nephrology therapies through strategic partnerships, enhancing its M&A attractiveness. The company's ecosystem creates unique kidney protection methods for rare pathologies, supported by a stable staff of specialized scientists. The EV/Sales trend reflects the market consensus on business valuation relative to revenue, where the current level of the metric is 0.00, reflecting the impact of global liquidity on share prices.
פילוחי מדדים פיננסיים ומדדי שוק עבור XORTX (XRTX)

For XORTX Therapeutics Inc. (XRTX), whose success depends on the outcome of clinical trials and patent protection, an unleveraged business valuation is critically important. This indicator compares the issuer's total market value with its annual revenue, allowing the GURU.Markets platform to determine the degree of overpayment for the drug's future potential via the Enterprise Value-to-Sales (EV/Sales) multiple.